Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)
Protocol ID
CA045020 / NKTR-214
Disease (Sub Disease)
All tumour types
Diagnosis Stage
Relapsed/refractory
Location
WA
Sponsor
Bristol-Myers Squibb
Collaborators
Nektar Therapeutics
Trial Status
Open
Sites
Perth Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
up to 30 years
International registry ID's
NCT04730349
Back to Registry
Study Title Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children Adolescents and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)
Protocol ID CA045020 / NKTR-214
Disease (Sub Disease) All tumour types
Diagnosis Stage Relapsed/refractory
Location WA
Sponsor Bristol-Myers Squibb
Collaborators Nektar Therapeutics
Links https://clinicaltrials.gov/ct2/show/NCT04730349
Trial Status Open
Trial Open Date 15/04/2021
Sites Perth Children's Hospital
Study Type Treatment
Phase Phase 1/2
Age Eligibility up to 30 years
International registry ID's NCT04730349